Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Denali Therapeutics Inc.’s reported figures.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s EBITDA?
- Denali Therapeutics Inc. (DNLI) reported EBITDA of -$126.97M in Q2 2026.
- How has Denali Therapeutics Inc.'s EBITDA changed year-over-year?
- Denali Therapeutics Inc.'s EBITDA increased by 3.7% year-over-year, from -$131.92M to -$126.97M.
- What is the long-term trend for Denali Therapeutics Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s EBITDA has grown at a 17.3% compound annual growth rate (CAGR), from -$287.16M to -$544.16M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Denali Therapeutics Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude